Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease. (CMM/EICH/2008)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2010 by Fundación Pública Andaluza Progreso y Salud.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Fundación Pública Andaluza Progreso y Salud
ClinicalTrials.gov Identifier:
NCT01222039
First received: October 14, 2010
Last updated: November 4, 2010
Last verified: October 2010
  Purpose

The main purpose of this trial is to assess the safety and feasibility of treatment with two-dose infusion of allogeneic mesenchymal stem cells from adipose tissue expanded in vitro in patients undergoing haematopoietic stem cell transplantation (HSCT, who have developed chronic and extensive graft versus host disease (GVHD).

Mesenchymal stem cells (MSCs) express low levels of HLA class I molecules, and do not express class II molecules neither CD40, CD80 and CD86, being unable to induce proliferation of allogeneic lymphocytes. In addition, MSCs inhibit lymphocyte proliferation by inhibiting cell division and maintaining these cells in a quiescent state. This supports the hypothesis that MSCs are universal suppressors.


Condition Intervention Phase
Graft Versus Host Disease
Chronic and Expanded Graft Versus Host Disease
Immune System Diseases
Drug: Conventional treatment
Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter Clinical Trial Phase I/II Randomized, Controlled, for the Evaluation of Safety and Feasibility of Therapy With Two Different Doses of Allogenic Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.

Resource links provided by NLM:


Further study details as provided by Fundación Pública Andaluza Progreso y Salud:

Primary Outcome Measures:
  • Number of adverse events [ Time Frame: 24 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Percentage of patients in each group that may potentially reduce corticosteroids at week 7, 20 and 42, started immunosuppressive treatment and percentage of patients at week 56 have been suspended on full immunosuppressive treatment [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Overall survival and disease-free survival. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Changes in lymphocyte subsets and levels of inflammatory and antiinflammatory cytokines in each of the groups. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: October 2010
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Conventional treatment plus high dose: 3x10e6 cells / Kg.
Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.

Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.

Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.

Experimental: Conventional treatment plus low dose: 1x10e6 cells / Kg
Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
Other: Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.

Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.

Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.

Conventional treatment.
Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
Drug: Conventional treatment
Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients who develop chronic extensive GVHD as determined by the National Institute of Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD (Biol Blood Marrow Transplant 2005; 11: 945-955), and which meet the following criteria:

  1. They have never received therapy for chronic GVHD.
  2. They have de novo or quiescent chronic extended GVHD.

Exclusion Criteria:

  1. Concomitant severe systemic infection.
  2. Oncologic or hematological condition relapse.
  3. Pregnancy.
  4. Estimated life expectancy less than 1 week.
  5. Patients who do not give their informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01222039

Contacts
Contact: Ana Cardesa +34 955 01 90 40

Locations
Spain
Hospital de Jerez de la Frontera. Recruiting
Jerez de la Frontera, Cádiz., Spain, 11407
Contact: Sebastián Garzón López, MD         
Hospital Universitario Virgen de las Nieves Recruiting
Granada., Spain, 18014.
Contact: Manuel Jurado, M.D         
Hospital Universitario Virgen del Rocío de Sevilla Recruiting
Sevilla, Spain, 41013
Contact: Ildefonso Espigado, M.D         
Hospital Clínico de Valencia Recruiting
Valencia, Spain, 46010
Contact: Carlos Solano Vercet, M.D         
Sponsors and Collaborators
Fundación Pública Andaluza Progreso y Salud
Investigators
Study Chair: Manuel Jurado Chacón, MD Haematology Department, Hospital Universitario Virgen de las Nieves de Granada. Spain.
Principal Investigator: Ildefonso Espigado, MD Haematology Department, Hospital Universitario Virgen del Rocío de Sevilla, Spain.
Principal Investigator: Carlos Solano Vercet, MD Haematology and Oncology Department. Hospital Clínico Universitario de Valencia, Spain.
Principal Investigator: Sebastián Garzón López., MD Hospital de Jerez de la Frontera, Cádiz. Spain.
  More Information

Additional Information:
No publications provided

Responsible Party: Juan Jesús Bandera, Managing Director., Fundación Progreso y Salud
ClinicalTrials.gov Identifier: NCT01222039     History of Changes
Other Study ID Numbers: EudraCT: 2008-004014-27
Study First Received: October 14, 2010
Last Updated: November 4, 2010
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by Fundación Pública Andaluza Progreso y Salud:
Graft versus host disease
Mesenchymal stem cell
Allogeneic mesenchymal stem cell
Adipose tissue
Allotransplant
Allogenic
Mesenchymal Stem Cells
Immune System Diseases
Chronic
Expanded

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases
Cyclosporine
Cyclosporins
Anti-Infective Agents
Antifungal Agents
Antirheumatic Agents
Dermatologic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on October 21, 2014